SCHEMBL1420175

SCHEMBL1420175

COC(=O)c1cc(O)c(O)c(Cl)c1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.74
KDM4E B2RXH2 3/20 0.74
XDH P47989 2/20 0.74
TDP1 Q9NUW8 2/20 0.74
POLB P06746 1/20 0.74
GAA P10253 1/20 0.74
NFKB1 P19838 1/20 0.74
GFER P55789 1/20 0.74
NFKB2 Q00653 1/20 0.74
RELA Q04206 1/20 0.74
FUT7 Q11130 1/20 0.74
L3MBTL1 Q9Y468 1/20 0.74
CA12 O43570 2/20 0.53
CA1 P00915 2/20 0.53
CA2 P00918 2/20 0.53
CA7 P43166 2/20 0.53
CA9 Q16790 2/20 0.53
CA14 Q9ULX7 2/20 0.53
TPMT P51580 1/20 0.51
CNR2 P34972 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL282150 0.90 KDM4E (0.63) LMNAKDM4EXDHTDP1POLB
Water SCHEMBL7957219 0.88 KDM4E (0.61) LMNAKDM4EXDHTDP1POLB
Gallic Acid Methyl Ester SCHEMBL39513 0.86 KDM4E (1.00) LMNAKDM4EXDHTDP1POLB
SCHEMBL197521 0.85 POLB (0.58) LMNAKDM4EXDHTDP1POLB
Gallic Acid Methyl Ester SCHEMBL28507408 0.84 KDM4E (0.95) LMNAKDM4EXDHTDP1POLB
Gallic Acid Methyl Ester SCHEMBL21543905 0.84 KDM4E (0.95) LMNAKDM4EXDHTDP1POLB
Gallic Acid Methyl Ester SCHEMBL21611341 0.84 KDM4E (0.95) LMNAKDM4EXDHTDP1POLB
Gallic Acid Methyl Ester SCHEMBL28556619 0.84 KDM4E (0.95) LMNAKDM4EXDHTDP1POLB
SCHEMBL401708 0.83 KDM4E (0.55) LMNAKDM4EXDHTDP1POLB
SCHEMBL9944141 0.83 LMNA (0.60) LMNAKDM4EXDHTDP1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10689371-B2 Modulators of methyl modifying enzymes, compositions and uses thereof CONSTELLATION PHARMACEUTICALS, INC. (US) 2020-06-23 US disclosed
US-20190322651-A1 MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF CONSTELLATION PHARMACEUTICALS, INC. 2019-10-24 US disclosed
US-9447028-B2 Therapeutic aryl-amido-aryl compounds and their use KING'S COLLEGE LONDON (GB) 2016-09-20 US disclosed
US-9447028-B2 Therapeutic aryl-amido-aryl compounds and their use KING'S COLLEGE LONDON (GB) 2016-09-20 US disclosed
US-9447028-B2 Therapeutic aryl-amido-aryl compounds and their use KING'S COLLEGE LONDON (GB) 2016-09-20 US disclosed
US-20160039747-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use KING'S COLLEGE LONDON (GB) 2016-02-11 US disclosed
US-20160039747-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use KING'S COLLEGE LONDON (GB) 2016-02-11 US disclosed
US-20160039747-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use KING'S COLLEGE LONDON (GB) 2016-02-11 US disclosed
US-9145425-B2 Cephem compound having catechol group SHIONOGI & CO., LTD. (JP) 2015-09-29 US disclosed
US-20130102583-A1 CEPHEM COMPOUND HAVING CATECHOL GROUP SHIONOGI & CO., LTD. (JP) 2013-04-25 US disclosed
WO-2011027106-A1 THERAPEUTIC ARYL-AM I DO-ARYL COMPOUNDS AND THEIR USE KING'S COLLEGE LONDON (GB) 2011-03-10 WO disclosed
US-20100029729-A1 COMPOUNDS GLAXO GROUP LIMITED (GB) 2010-02-04 US disclosed
US-20100029729-A1 COMPOUNDS GLAXO GROUP LIMITED (GB) 2010-02-04 US disclosed
US-20100029729-A1 COMPOUNDS GLAXO GROUP LIMITED (GB) 2010-02-04 US disclosed
US-20100010053-A1 COMPOUNDS GLAXO GROUP LIMITED (GB) 2010-01-14 US disclosed
US-20100010053-A1 COMPOUNDS GLAXO GROUP LIMITED (GB) 2010-01-14 US disclosed
US-20100010053-A1 COMPOUNDS GLAXO GROUP LIMITED (GB) 2010-01-14 US disclosed
WO-2009153307-A1 COMPOUNDS GLAXO GROUP LIMITED (GB) 2009-12-23 WO disclosed
WO-2009153307-A1 COMPOUNDS GLAXO GROUP LIMITED (GB) 2009-12-23 WO disclosed
EP-0400805-A1 Cephalosporin compounds and their use Ishimaru, Toshiyasu (JP) 1990-12-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190322651-A1 MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF TPMT, TET1, DNMT1 LMNA 3267/4885KDM4E 75/4885XDH 198/4885
US-20130102583-A1 CEPHEM COMPOUND HAVING CATECHOL GROUP COMT, EZH1, SETD7 LMNA 2405/4885KDM4E 586/4885XDH 315/4885
US-20100029729-A1 COMPOUNDS CYP11B2, CYP11B1, GLS2 LMNA 2248/4885KDM4E 4128/4885XDH 106/4885
US-10689371-B2 Modulators of methyl modifying enzymes, compositions and uses thereof TPMT, TET1, DNMT1 LMNA 3267/4885KDM4E 75/4885XDH 198/4885
US-20100010053-A1 COMPOUNDS CYP11B2, CYP11B1, GLS2 LMNA 2248/4885KDM4E 4128/4885XDH 106/4885
US-20160039747-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use RARA, RARB, RARG LMNA 1825/4885KDM4E 2548/4885XDH 953/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.